Drug intelligence / Profile preview

GC3102C

Development stage: Phase 3
Lead developer: GC Biopharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GC3102C is a prophylactic influenza virus vaccine developed by GC Biopharma (formerly GC Pharma, also known as Green Cross Corporation). It is designed to provide immunization against influenza virus infection. The vaccine has undergone Phase III clinical trials to evaluate its immunogenic efficacy and safety compared to GC FLU injection when administered intramuscularly in healthy adults.

Other names: Influenza virus vaccine

Beyond the preview

Go deeper on GC3102C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC3102C.

Explore the full profile